 Gilead Sciences Inc. GILD, 1.91 said Friday that it will co-develop and co-commercialize Arcellx Inc.s ACLX, 7.22 multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcellx 225 million upfront, plus make a 100 million equity investment in the company. 